Norcliffe Capital is a specialist investment firm focused on early-stage MedTech and biotech companies that are transforming patient outcomes and redefining healthcare delivery. With a deep commitment to the Enterprise Investment Scheme (EIS), Norcliffe supports pioneering ventures that combine scientific excellence with commercial potential.
At the heart of Norcliffe’s approach is a belief in “Profit with a Purpose”, a guiding principle that ensures every investment not only seeks financial return but also delivers measurable societal benefit. This ethos drives Norcliffe to back founders who are solving real-world problems, from diagnostics and digital therapeutics to advanced medical devices.
Norcliffe actively engages with the EISA community to promote the value of EIS in accelerating innovation, supporting UK-based talent, and building a healthier future. Through strategic capital, hands-on support, and a purpose-led mindset, Norcliffe Capital is helping shape the next generation of life-changing technologies.